Sandoz, CH1243598427

Sandoz stock: Enzeevu US launch adds private-label channel

Published on 11/21/2026 at 12:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sandoz stock enters a new US commercial phase with Enzeevu. A private-label agreement adds committed volumes from the second half of 2027.

Commercial Reach Expands In The United States

  • Sandoz launched Enzeevu in the United States on November 16, 2026.
  • The medicine is approved for several retinal diseases and is interchangeable with the reference medicine for approved indications.
  • The company targets more than 100 biosimilars in its portfolio by 2040.
Sandoz, CH1243598427, Illustration mit AI erstellt.

Sandoz launched its Enzeevu biosimilar in the United States on November 16, 2026, alongside a multi-year private-label agreement. The company said the arrangement will broaden access to the ophthalmology product and expand its US commercial reach. The announcement was made in a Sandoz media release.

US launch broadens commercial reach

Enzeevu is aflibercept-abzv 2 mg in a pre-filled syringe. Sandoz said it is approved for several retinal diseases, including wet age-related macular degeneration, macular edema following retinal vein occlusion, diabetic retinopathy and diabetic macular edema.

Alongside its own-label launch, Sandoz will manufacture Enzeevu for commercialisation under a private label beginning in mid-2027. The company said committed volumes will start in the second half of 2027, while financial terms were not disclosed in the announcement.

Bio100 keeps biosimilars central

The launch supports Sandoz's Bio100 ambition to build a portfolio of more than 100 biosimilars by 2040. The company said the move strengthens its ophthalmology position after its acquisition of Cimerli in 2024 and the European launch of Afqlir in 2025.

Enzeevu is interchangeable with the reference medicine for all approved indications, according to Sandoz. The company said the US anti-VEGF market is worth an estimated 9.6 billion US dollars, framing the launch as part of its broader biosimilar expansion.

Sandoz stock last traded at 86.69 euros on Lang & Schwarz at 12:15 CET on Saturday, November 21, 2026.

Sandoz Group AG

  • Company: Sandoz Group AG
  • ISIN: CH1243598427
  • Primary listing: SIX Swiss Exchange, ticker SDZ
  • Latest quote: 86.69 euros on Lang & Schwarz, Saturday, November 21, 2026, at 12:15 CET

The broader market backdrop is available in Current market reports.

More news and analyses on Sandoz stock

Disclaimer...
en | CH1243598427 | SANDOZ | boerse | 70542435 | bgmi